• Ocrevus’ Journey from Defiant Idea to Game-Changing Treatment
  • 39 Years and Counting — on at Least 39 More Great Ones
  • Sanofi Genzyme to Present New Data on MS Treatments Lemtrada and Aubagio
  • Why the Future of Science Is Crucial to the MS Community
  • Bioinformatics Approach Identifies Potential Therapies Targeting TNF, a Factor in MS, Other Diseases
  • Latest Tecfidera and Tysabri Data Suggest Treatments Improve MS Outcomes When Used Early
  • Chronic Illness and End-of-Life Decisions: Who are We to Judge?
  • Real-world Data of Gilenya Treatment Validates Slowed Brain Shrinkage as Disease Progression Measure
  • MS, Wheelchairs, Walkers and Guns: Are They Safe Together?
  • Hypothyroidism and What It Shares with MS
  • ATA188, Which Kills B-Cells Targeting Epstein-Barr Virus, Shows Promise as MS Treatment
  • Glove with Sensors Measures Spasticity More Accurately than Physicians
  • The Cluttered Consequences of Multiple Sclerosis Fatigue